EGFR and non-small cell lung carcinoma: The application to TKI-resistant NSCLC model study reveals, for the first time, on how EGFR mutation altered its glycosylation, phosphorylation, and downstream phosphorylation cascade, providing valuable insights into TKI resistance and potential therapeutic targets that warrant further functional validation.